blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3572511

EP3572511 - COMPLEX CONTAINING OLIGONUCLEOTIDE HAVING IMMUNOPOTENTIATING ACTIVITY AND USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.05.2024
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  09.06.2023
FormerGrant of patent is intended
Status updated on  06.02.2023
FormerExamination is in progress
Status updated on  25.09.2020
FormerRequest for examination was made
Status updated on  29.05.2020
FormerThe application has been published
Status updated on  25.10.2019
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): BE, SI		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
National Institutes of Biomedical Innovation, Health and Nutrition
7-6-8, Saito-Asagi
Ibaraki-shi, Osaka 567-0085 / JP
For all designated states
Daiichi Sankyo Company, Limited
3-5-1, Nihonbashi Honcho
Chuo-ku
Tokyo 103-8426 / JP
[2019/48]
Inventor(s)01 / ISHII, Ken
c/o National Institute of Biomedical Innovation
Health and Nutrition
7-6-8, Saito-Asagi
Ibaraki-shi, Osaka 567-0085 / JP
02 / KOBIYAMA, Kouji
c/o National Institute of Biomedical Innovation
Health and Nutrition
7-6-8, Saito-Asagi
Ibaraki-shi, Osaka 567-0085 / JP
03 / AOSHI, Taiki
c/o National Institute of Biomedical Innovation
Health and Nutrition
7-6-8, Saito-Asagi
Ibaraki-shi, Osaka 567-0085 / JP
04 / TAKESHITA, Fumihiko
c/o Daiichi Sankyo Company Limited
3-5-1 Nihonbashi Honcho
Chuo-ku, Tokyo 103-8426 / JP
05 / KASUYA, Yuji
c/o Daiichi Sankyo Company Limited
1-2-58 Hiromachi
Shinagawa-ku, Tokyo 140-8710 / JP
06 / NIWA, Takako
c/o Daiichi Sankyo Company Limited
1-2-58 Hiromachi
Shinagawa-ku, Tokyo 140-8710 / JP
07 / KOIZUMI, Makoto
c/o Daiichi Sankyo Company Limited
1-2-58 Hiromachi
Shinagawa-ku, Tokyo 140-8710 / JP
 [2019/48]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/28]
Former [2019/48]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19182054.719.09.2014
[2019/48]
Priority number, dateJP2013019620620.09.2013         Original published format: JP 2013196206
[2019/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3572511
Date:27.11.2019
Language:EN
[2019/48]
Type: B1 Patent specification 
No.:EP3572511
Date:12.07.2023
Language:EN
[2023/28]
Search report(s)(Supplementary) European search report - dispatched on:EP11.10.2019
ClassificationIPC:A61K31/7125, A61K31/713, A61K39/00, A61K39/02, A61K39/12, A61K39/145, A61K39/155, A61K39/39, A61P31/04, A61P31/12, A61P33/00, A61P35/00, A61P37/04, A61P37/08, A61P43/00, C08B37/00, C07H21/04, C12N15/09, C12N15/117
[2023/09]
CPC:
C12N15/117 (EP,KR,RU,US); A61K31/7125 (EP,KR,RU,US); A61K39/39 (EP,KR,RU,US);
A61K31/713 (EP,KR,RU,US); A61K39/12 (EP,RU,US); A61K39/145 (EP,KR,RU,US);
A61K39/155 (EP,KR,RU,US); A61K47/61 (KR); A61K47/6939 (KR);
A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP,KR);
A61P31/14 (EP); A61P31/16 (EP); A61P33/00 (EP);
A61P35/00 (EP,KR); A61P37/00 (EP); A61P37/04 (EP);
A61P37/08 (EP,KR); A61P43/00 (EP); C07H21/04 (EP,KR,RU,US);
C08B37/0024 (EP,RU,US); C12N7/00 (RU,US); A61K2039/5252 (EP,US);
A61K2039/55561 (KR,US); A61K2039/55583 (EP,KR,US); C12N2310/17 (EP,US);
C12N2310/315 (EP,KR,US); C12N2310/351 (US); C12N2310/3519 (EP,US);
C12N2320/31 (EP,US); C12N2760/16134 (EP,US); C12N2760/18534 (EP,US);
Y02A50/30 (EP) (-)
Former IPC [2019/48]C12N15/09, A61K31/7125, A61K31/713, A61K39/02, A61K39/12, A61K39/39, A61P31/04, A61P31/12, A61P33/00, A61P35/00, A61P37/04, A61P37/08, A61P43/00, C07H21/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/27]
Former [2019/48]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:KOMPLEX MIT EINEM OLIGONUKLEOTID MIT IMMUNPOTENZIERENDER WIRKUNG UND VERWENDUNG DAVON[2019/48]
English:COMPLEX CONTAINING OLIGONUCLEOTIDE HAVING IMMUNOPOTENTIATING ACTIVITY AND USE THEREOF[2019/48]
French:COMPLEXE CONTENANT UN OLIGONUCLÉOTIDE PRÉSENTANT UNE ACTIVITÉ IMMUNOPOTENTIALISATRICE ET SON UTILISATION[2019/48]
Examination procedure27.05.2020Amendment by applicant (claims and/or description)
27.05.2020Examination requested  [2020/27]
27.05.2020Date on which the examining division has become responsible
24.09.2020Despatch of a communication from the examining division (Time limit: M04)
01.02.2021Reply to a communication from the examining division
28.05.2021Despatch of a communication from the examining division (Time limit: M04)
27.09.2021Reply to a communication from the examining division
07.02.2023Communication of intention to grant the patent
01.06.2023Fee for grant paid
01.06.2023Fee for publishing/printing paid
01.06.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14846493.6  / EP3048170
Divisional application(s)EP23176351.7  / EP4253546
Opposition(s)15.04.2024No opposition filed within time limit [2024/25]
Fees paidRenewal fee
24.06.2019Renewal fee patent year 03
24.06.2019Renewal fee patent year 04
24.06.2019Renewal fee patent year 05
01.07.2019Renewal fee patent year 06
14.09.2020Renewal fee patent year 07
15.09.2021Renewal fee patent year 08
11.08.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
MC12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SI12.07.2023
SK12.07.2023
SM12.07.2023
IE19.09.2023
LU19.09.2023
BE30.09.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
[2024/36]
Former [2024/33]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
MC12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SK12.07.2023
SM12.07.2023
IE19.09.2023
LU19.09.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/28]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
MC12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SK12.07.2023
SM12.07.2023
LU19.09.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/25]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SK12.07.2023
SM12.07.2023
LU19.09.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/23]AT12.07.2023
CZ12.07.2023
DK12.07.2023
EE12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SK12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/22]AT12.07.2023
CZ12.07.2023
DK12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RO12.07.2023
RS12.07.2023
SE12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/20]AT12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RS12.07.2023
SE12.07.2023
SM12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/10]AT12.07.2023
FI12.07.2023
HR12.07.2023
LT12.07.2023
LV12.07.2023
NL12.07.2023
PL12.07.2023
RS12.07.2023
SE12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
PT13.11.2023
Former [2024/09]AT12.07.2023
FI12.07.2023
LT12.07.2023
NL12.07.2023
SE12.07.2023
NO12.10.2023
GR13.10.2023
IS12.11.2023
Former [2024/08]LT12.07.2023
NL12.07.2023
NO12.10.2023
GR13.10.2023
Former [2024/05]NL12.07.2023
Documents cited:Search[Y]US2003026782  (KRIEG ARTHUR M [US]) [Y] 1-15 * table 1; sequence 2a *;
 [X]  - HIROKO MIYAMOTO ET AL, "Selective Delivery of Oligonucletide Using a beta-1,3-glucan Receptor", CELLULOSE COMMUNICATIONS, UJI, JP, (20120101), vol. 19, no. 1, ISSN 1342-730X, pages 12 - 16, XP008183343 [X] 1-15 * figures 1-3 *
 [XYI]  - JUSAKU MINARI ET AL, "Enhanced Cytokine Secretion from Primary Macrophages due to Dectin-1 Mediated Uptake of CpG DNA/[beta]-1,3-Glucan Complex", BIOCONJUGATE CHEMISTRY, (20110119), vol. 22, no. 1, doi:10.1021/bc1001196, ISSN 1043-1802, pages 9 - 15, XP055317850 [X] 1-4,8,10,13,14 * page 10, column l, paragraph 1; figures 1-7 * [Y] 1-15 [I] 5-7,9,11,12,15

DOI:   http://dx.doi.org/10.1021/bc1001196
 [Y]  - FUMIHIKO TAKESHITA ET AL, "Role of toll-like receptor 9 in CpG DNA-induced activation of human cells", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20011001), vol. 167, no. 7, ISSN 0022-1767, pages 3555 - 3558, XP002979099 [Y] 1-15 * figures 1-4 *
 [Y]  - TAKAHIRO TOUGAN ET AL, "TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models", HUMAN VACCINES & IMMUNOTHERAPEUTICS, United States, (20130201), vol. 9, no. 2, doi:10.4161/hv.22950, ISSN 2164-5515, pages 283 - 290, XP055357144 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.4161/hv.22950
 [T]  - BURCU TEMIZOZ ET AL, "Vaccine adjuvants as potential cancer immunotherapeutics", INTERNATIONAL IMMUNOLOGY., GB, (20160322), vol. 28, no. 7, doi:10.1093/intimm/dxw015, ISSN 0953-8178, pages 329 - 338, XP055356653 [T] 1-15 * page 334, column r, paragraph 6 - page 335, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1093/intimm/dxw015
Examination   - KITAHATA YUJI ET AL, "Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells", ONCOTARGET, United States, (20160802), vol. 7, no. 31, doi:10.18632/oncotarget.10379, ISSN 1949-2553, pages 48860 - 48869, XP055801528

DOI:   http://dx.doi.org/10.18632/oncotarget.10379
by applicantWO9526204
 WO0134207
 WO02072152
 JP2004107272
 WO2004100965
 JP2007070307
 JP2008100919
 JP2010174107
 US8030285
 JP2013196206
    - HEMMI, H. et al., "A Toll-like receptor recognizes bacterial DNA", Nature, (20000000), vol. 408, doi:doi:10.1038/35047123, pages 740 - 745, XP002221246

DOI:   http://dx.doi.org/10.1038/35047123
    - KRIEG, A.M., "Therapeutic potential of Toll-like receptor 9 activation", Nature reviews. Drug discovery, (20060000), vol. 5, doi:doi:10.1038/nrd2059, pages 471 - 484, XP008109144

DOI:   http://dx.doi.org/10.1038/nrd2059
    - BRAZOLOT MILLAN, C.L.WEERATNA, R.KRIEG, A.M.SIEGRIST, C.A.DAVIS, H.L., "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", Proceedings of the National Academy of Sciences of the United States of America, (19980000), vol. 95, doi:doi:10.1073/pnas.95.26.15553, pages 15553 - 15558, XP002148908

DOI:   http://dx.doi.org/10.1073/pnas.95.26.15553
    - CHU, R.S.TARGONI, O.S.KRIEG, A.M.LEHMANN, P.V.HARDING, C.V., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Thl) immunity", The Journal of experimental medicine, (19970000), vol. 186, doi:doi:10.1084/jem.186.10.1623, pages 1623 - 1631, XP002910130

DOI:   http://dx.doi.org/10.1084/jem.186.10.1623
    - KLINMAN, D.M., "Immunotherapeutic uses of CpG oligodeoxynucleotides", Nature reviews. Immunology, (20040000), vol. 4, doi:doi:10.1038/nri1329, pages 249 - 258, XP003006450

DOI:   http://dx.doi.org/10.1038/nri1329
    - VOLLMER, J.KRIEG, A.M., "Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists", Advanced drug delivery reviews, (20090000), vol. 61, doi:doi:10.1016/j.addr.2008.12.008, pages 195 - 204, XP025972624

DOI:   http://dx.doi.org/10.1016/j.addr.2008.12.008
    - KRUG, A. et al., "Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells", European journal of immunology, (20010000), vol. 31, doi:doi:10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U, pages 2154 - 2163, XP002292085

DOI:   http://dx.doi.org/10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
    - VERTHELYI, D.ISHII, K.J.GURSEL, M.TAKESHITA, F.KLINMAN, D.M., "Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs", Journal of immunology, (20010000), vol. 166, pages 2372 - 2377, XP002299044
    - HARTMANN, G.KRIEG, A.M., "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", Journal of immunology, (20000000), vol. 164, pages 944 - 953
    - HARTMANN, G. et al., "Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells", European journal of immunology, (20030000), vol. 33, doi:doi:10.1002/eji.200323813, pages 1633 - 1641, XP009015493

DOI:   http://dx.doi.org/10.1002/eji.200323813
    - MARSHALL, J.D. et al., "Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions", Journal of leukocyte biology, (20030000), vol. 73, doi:doi:10.1189/jlb.1202630, pages 781 - 792, XP002497698

DOI:   http://dx.doi.org/10.1189/jlb.1202630
    - SAMULOWITZ, U. et al., "A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties", Oligonucleotides, (20100000), vol. 20, doi:doi:10.1089/oli.2009.0210, pages 93 - 101, XP055360581

DOI:   http://dx.doi.org/10.1089/oli.2009.0210
    - KERKMANN, M. et al., "Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells", The Journal of biological chemistry, (20050000), vol. 280, doi:doi:10.1074/jbc.M410868200, pages 8086 - 8093, XP002454062

DOI:   http://dx.doi.org/10.1074/jbc.M410868200
    - KLEIN, D.C.LATZ, E.ESPEVIK, T.STOKKE, B.T., "Higher order structure of short immunostimulatory oligonucleotides studied by atomicforce microscopy", Ultramicroscopy, (20100000), vol. 110, doi:doi:10.1016/j.ultramic.2010.02.033, pages 689 - 693, XP027064230

DOI:   http://dx.doi.org/10.1016/j.ultramic.2010.02.033
    - PUIG, M. et al., "Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN D type: structural studies and immunomodulatory activity in primates", Nucleic acids research, (20060000), vol. 34, doi:doi:10.1093/nar/gkl867, pages 6488 - 6495, XP055001852

DOI:   http://dx.doi.org/10.1093/nar/gkl867
    - BODE, C.ZHAO, G.STEINHAGEN, F.KINJO, T.KLINMAN, D.M., "CpG DNA as a vaccine adjuvant", Expert review of vaccines, (20110000), vol. 10, doi:doi:10.1586/erv.10.174, pages 499 - 511, XP055551929

DOI:   http://dx.doi.org/10.1586/erv.10.174
    - MCHUTCHISON, J.G. et al., "Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus", Hepatology, (20070000), vol. 46, pages 1341 - 1349
    - OKAMURA, K. et al., "Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study", Cancer, (19860000), vol. 58, pages 865 - 872
    - OBA, K.KOBAYASHI, M.MATSUI, T.KODERA, Y.SAKAMOTO, J., "Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer", Anticancer Res., (20090000), vol. 29, pages 2739 - 2746
    - NAKANO, H.NAMATAME, K.NEMOTO, H.MOTOHASHI, H.NISHIYAMA, K.KUMADA, K., "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life", Hepato-Gastroenterol., (19990000), vol. 46, pages 2662 - 2668
    - SAKURAI, K.MIZU, M.SHINKAI, S., "Polysaccharide-polynucleotide complexes. 2. Complementary polynucleotide mimic behavior of the natural polysaccharide schizophyllan in the macromolecular complex with single- stranded RNA and DNA", Biomacromolecules, (20010000), vol. 2, doi:doi:10.1021/BM000121R, pages 641 - 650, XP002504242

DOI:   http://dx.doi.org/10.1021/BM000121R
    - SHIMADA, N. et al., "A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells", Bioconjugate chemistry, (20070000), vol. 18, doi:doi:10.1021/bc0700178, pages 1280 - 1286, XP055145914

DOI:   http://dx.doi.org/10.1021/bc0700178
    - KOYAMA, S. et al., "Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes", Science translational medicine, (20100000), vol. 2, doi:doi:10.1126/scitranslmed.3000759, page 25ra24, XP055229166

DOI:   http://dx.doi.org/10.1126/scitranslmed.3000759
    - MINARI, J. et al., "Enhanced cytokine secretion from primary macrophages due to Dectin-1 mediated uptake of CpG DNA/beta-1,3-glucan complex", Bioconjugate chemistry, (20110000), vol. 22, doi:doi:10.1021/bc1001196, pages 9 - 15, XP055317850

DOI:   http://dx.doi.org/10.1021/bc1001196
    - Advanced drug delivery reviews, (20090000), vol. 61, pages 195 - 204
    - VERTHELYI, D. et al., Journal of immunology, (20010000), vol. 166, pages 2372 - 2377
    - Journal of immunology, (20000000), vol. 164, pages 944 - 953
    - HAMURO, J. et al., Immunology, (19800000), vol. 39, pages 551 - 559
    - HAMURO, J. et al., Int. J. Immunopharmacol., (19800000), vol. 2, page 171
    - HERLYN, D. et al., Gann, (19850000), vol. 76, pages 37 - 42
    - TABATA, K.ITO, W.KOJIMA, T.KAWABATA, S.MISAKI A., Carbohydr. Res., (19810000), vol. 89, no. 1, pages 121 - 135
    - SHIMIZUCHINHASUMIMASUBUCHI, Biotherapy, (19900000), vol. 4, page 1390
    - HASEGAWA, Oncology and Chemotherapy, (19920000), vol. 8, page 225
    - THERESA, M. MCINTIREDAVID, A. BRANT, J. Am. Chem. Soc., (19980000), vol. 120, page 6909
    - KOYAMA, S. et al., Science translational medicine, (20100000), vol. 2, page 25ra24
    - SAIJO, S. et al., Nature immunology, (20070000), vol. 8, pages 39 - 46
    - SHIMADA, N. et al., Bioconjugate chemistry, (20070000), vol. 18, pages 1280 - 1286
    - MINARI, J. et al., Bioconjugate chemistry, (20110000), vol. 22, pages 9 - 15
    - BAE, A.H. et al., Carbohydrate research, (20040000), vol. 339, pages 251 - 258
    - KLEIN, D.C. et al., Ultramicroscopy, (20100000), vol. 110, pages 689 - 693
    - COSTA, L.T. et al., Biochemical and biophysical research communications, (20040000), vol. 313, pages 1065 - 1072
    - KRUG, A. et al., European journal of immunology, (20010000), vol. 31, pages 2154 - 2163
    - GURSEL, M. et al., Journal of leukocyte biology, (20020000), vol. 71, pages 813 - 820
    - GUIDUCCI, C. et al., The Journal of experimental medicine, (20060000), vol. 203, pages 1999 - 2008
    - HERRE, J. et al., Blood, (20040000), vol. 104, pages 4038 - 4045
    - GOODRIDGE, H.S. et al., Nature, (20110000), vol. 472, pages 471 - 475
    - EBERLE, M.E.DALPKE, A.H., Journal of immunology, (20120000), vol. 188, pages 5644 - 5654
    - HEMMI, H. et al., Nature, (20000000), vol. 408, pages 740 - 745
    - MARTINEZ-POMARES, L.GORDON, S., Trends in immunology, (20120000), vol. 33, pages 66 - 70
    - AOSHI, T. et al., European journal of immunology, (20090000), vol. 39, pages 417 - 425
    - GRAY, E.E.CYSTER, J.G., Journal of innate immunity, (20120000), vol. 4, pages 424 - 436
    - GONZALEZ, S.F. et al., Nature immunology, (20100000), vol. 11, pages 427 - 434
    - SUZUKI, K. et al., The Journal of experimental medicine, (20090000), vol. 206, pages 1485 - 1493
    - AOSHI, T. et al., Immunity, (20080000), vol. 29, pages 476 - 486
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.